ERRATUM article

Front. Pharmacol., 27 January 2022

Sec. Experimental Pharmacology and Drug Discovery

Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.849039

Erratum: Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis

This article is an erratum on:

  1. Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis

    1. Read original article
Frontiers Production Office Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

An erratum on
Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis

by Srivastava, S., Thomas, T., Howe, D., Malinga, L., Raj, P., Alffenaar, J.-W., and Gumbo, T. (2021). Front. Pharmacol. 12:677005. doi: 10.3389/fphar.2021.677005

Due to production error, an existing conflict of interest between one of the reviewers and the authors was not declared. The updated Conflict of Interest statement has been included below.

The publisher apologizes for this mistake. The original version of this article has been updated.

Conflict of Interest

TG is founder and CEO of Praedicare Inc. DH is an employee of Praedicare Inc.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer JGP declared past co-authorships with several of the authors, SS, TT, LM, PR, J-WA, and TG, and states that the process nevertheless met the standards of a fair and objective review.

Keywords: cephalosporins, avibactam, hollow fiber model, multi-drug resistance, pharmacokinetics/pharmacodynamics

Citation: (2022) Erratum: Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis. Front. Pharmacol. 13:849039. doi: 10.3389/fphar.2022.849039

Received: 05 January 2022; Accepted: 05 January 2022;
Published: 27 January 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.